and day Chris, everyone. good you, Thank
new provided We impact are and is three. a slide on pleased quarter. dominate cycle which to this update of number the during continued on quarter, our progress everyday summary this COVID-XX life to
and employees safe. the We our are working regional guidelines local keep to within
we on the and fronts. are adapted to have We executing new paradigm, all
future to landscape. may further pandemic the that to is are We and ongoing, need adapt changing the the in mindful
MD of the with of specifically first at Anderson. TCR-T dosing patient where the this to advance provide our a program, the review X NCI First, continue I we Starting in Phase will towards has our programs, Rosenberg safely NCI, informed an possible, and at by all quickly NCI and urgency the back trial laboratory incrementally online. functions as dosing are begin the as Steven coming feel us led that Dr. and to
updates, Houston, undertook runs information earlier help now the reopen plans NCI on Rosenberg's in relayed engineering their mentioned was our ongoing facility Dr. accelerate pandemic. at they NCI to enrollment the to As team back we during as the shutdown, and that have while
In screen addition, to needed. beginning for the trial. and them proactively for TCRs to receptors they're to patients or neoantigens referrals eligible is This T-cell render
appreciate support, As to lost to a anticipated pandemic unfortunately you result and resulting the were be their patients progress. shutdowns, of progression forward of who due some look to their strong and the treated NCI's disease. We updating of the malignant were on
and the personalized that neoantigens campus Now, is establishing for turning identify running Anderson that ZIOPHARM's in to are the our TCR-T bioinformatics TCR-T Center commercially-oriented TCR-T facilities from to Houston; alongside library and our MD are and program staff we laboratory the programs. Cancer TCRs
improve time. database, the a addition the In that to we ourselves, hotspots. we our are the receptors anticipated screening or the creating a modified genetically the over Thus, powerful patient are library. grow can identified a enlarging in-licensing identifying library using continue TCR during asset T-cells through receive we the process by and will to from program, which added chance neoantigens internal to in expanding of NCI, targeting our shared to number library further The expect from in identification additional in-license continue thus from TCRs of receptors TCRs to
package. We and or application New given NCI, the have work the the IND FDA on Drug in our Investigational jumpstart Houston, pre-IND on feedback at from company's a the the
targets regulatory cancers submit cholangiocarcinoma. the submission IND the this This our our utilized multiple and the will focused such on application pancreatic, cell year, CMC, and cancer, of gynecologic, likely anticipated the colorectal, a as TCRS. submission guidance that will for mid-XXXX. beginning be to ZIOPHARM's non-clinical for are company This means generating its non-small and we time, early that target could IND multiple progress human received the initially IND-enabling of in streamline save in helpful obtained lung submission feedback FDA enrollments with data us teams sponsored planned In earlier Our XXXX IND.
terrific our the TCR-T the initially we then library, plan TCR-T this Given to momentum arm and enroll ZIOPHARM sponsored to enroll under our building personalized to IND, arm.
in licensing way pace trial approximately sponsored clinical of rapid have core from dosing highlighting we of the progressed to the As years. in of two TCR-T work, our the anticipated technology a ZIOPHARM's
Controlled trial in at have to tumors study the we under program, in Cancer DIPG our care Moving Goldman. extends controlled disease X/X pediatric technology. Recurrent of upon IL-XX the our another experience the Center value type, Chicago asset This or IL-XX Dr. Lurie in our and brain into platform Phase dosed first building a thus as of patient Glioblastoma with Stuart builds rGBM,
the study study Thanks with time of of milligrams for favorable combination the inhibitor. we XX trial, and that patients. veledimex. to X are Francisco. in In economics This potential efficacy safety the Cancer received of at evaluated, children given designed enrollment provides Other we in DIPG resection, participating the which trial of to portion injection Boston, Farber another patients in in rGBM, anticipated the IL-XX patients IL-XX with controlled designed with sites. and a intratumorally IL-XX enrollment surgical XX regulatory Additional initial plus in days. commercial evaluate path as evaluate combination clinicians for the veledimex and XX PD-X the in and and tolerability of dedication with a rGBM of referral to Phase the QX ongoing University Dana centers being appear Regeneron's targeting single-intratumoral Libtayo approval with are and of oral with safety addition the to Ad-RTS-hIL-XX, trial targeting Institute company. The is completed for are of our with our controlled San along the California, pediatric a is of DIPG of oral timeline patients XX in
until from the withdrawal or documented three are study. also As designed, Libtayo patients receiving progression intravenous every weeks
clinical or Meeting, additional clinical expect Rapid Our bound RPM. the were the CAR, produced to to In one membrane Manufacturing this scientific Eden Personalized data Society Oncology coordinating presented clinical BioCell, monotherapy with for at year. in Taiwan an the conferences IND a trial IND program, from for and posters filing our joint Taiwan CAR-T IND co-expressed more CDE of our pleased all this studies we preliminary present American trial three underway ZIOPHARM or year's CDXX-specific later and activities. TriArm be with teams Virtual and process Drug between proposed in Therapeutics, and TriArm autologous at or combination of filed with Clinical for package and scientific venture Annual with using the membrane a has IL-XX, assessment Center Evaluation bound a is
additional CDXX the to of on expertise As in future. RPM be year. approval is considering for expedite and by anticipated the CAR-T to network to process final CDE of the anticipated facilitate submission Taiwan. day actively enables a the and China, CAR-T team after studies gene one is extensive the first their Based the of TriArm program infused is Taiwanese reminder, by transfer. potentially assessment expected this sites trial IND be This CAR-T in the trial end autologous clinical in clinical This the Greater
in Program in after thing of from accomplished bone shortly. expressing we as the begin study. is marrow have derived will with patients T commence our specific This the who we MD allogeneic anticipate study CDXX relapsed this malignancies, cells have emerges CAR-T MD and shutdown secured COVID-XX with CDXX Anderson, Regarding at donor transplantation, enrollment approval importance that and those Anderson was of its validation to
trial open data enrollments IL-XX third, on and this fourth, To in make first excited study in ASCO initiating enrollment our pleased DIPG our CDXX-Specific this about in IL-XX study; X autologous allogenic CD-XX We and regulatory to controlled study; RPM X year's we past CAR-T progress at for quarter Anderson. the are undertaking specific our controlled Phase partners conference; that Phase study CAR-T have MD completing in are summarize, the for lastly at patient pediatric we to the X IL-XX; second, opportunity. first Taiwan including, dosing additional controlled combo and our clinical RPM filings Phase presenting
James which continue process, of Board we currently to search side, the Huang board. outcome and The recently is addition of the year, the announce corporate our our feedback of board announced considering to the potential we opportunities began Directors. management. year, strengthen the on earlier to received. our On are the our had Directors upon beginning the as Board of additions at and/or had deliberating we end, were pursue to pleased and recent Building this the To to meeting replacements annual this
June Carl or are beginning building our Advisory Dr. also We Board SAP, out as Chair. Scientific with
a recruit to look ongoing. discussed have and we Chief search Officer, we to other is the changes, Medical plans previously As
to programs. a NCI of ZIOPHARM, and an out participate collaborative leaders for reporting me. also to strengthen Dr. providing the an analysts we which right investment this from for opportunity and day, the senior our executives time and is the strengthen to time addition, search for exciting time for right In opportunities team. the board senior initiated also is is build team The to look an for as and R&D hear clinical as to our be event, will Rosenberg community from fall. our for scheduled had agreed shareholders, of the already others members other to team, an well This
also details ago. with an the much XX date time you forging to technology forward plans about showcase independence This looking further We since and appropriate have are as approaches. is to our as accomplished so we sharing months
Beauty infrastructure in our rapidly company. provides and Beauty T-cells summarize goals. necessary XXXX FDA under for in This of first these partner We have cutting-edge Sleeping and leadership NCI. overview Steven separated cleared the independent has are non-viral of NCI solid October science utilized technology direction We We neoantigens. the Slide the technologies, the established here. in key internal is at platform developing library foreigner place to a accomplish tumor and hotspot an Phase events and put a Sleeping to with XXXX, unique and operate infusing TCR-T four Rosenberg. TCR-T from program an now TCR targeting Dr. our the from using recruitment The briefly X licensing support IND of leading-edge as an system, our cost-effectively trial, modified of
for our MD relationship received with independent added from the first space TCR-T ZIOPHARM the clinical feedback expanded Anderson FDA new campus, MD Anderson sponsored and on trial. important and Forged
are have establish completed program. contributions building the team as we first, in left similar targeting supporting the and expansion, TCR-T significant the of We providing in trial which as our personalized Anderson, for MD to for Despite already second, has phase corporate and NCI. team the hotspot, out planned the a in to ongoing clinical targeting library the pandemic, program of the our initial The early Houston, our unique in path commercial IND meaningful two arms; the neoantigens our is made expeditiously TCR-T at the made antigens shared Houston data TCR-T to progress We prepare capabilities such we NCI. XXXX.
Next U.S. formed We TriArm Therapeutics. our our new venture recently in with the a CDXX by partner BioCell targeting called Anderson study at aimed CAR-T. MD China, funding we RPM our Eden platform Greater further validating with joint in at initiated committed
first file Taiwan. have and year facilities a that The additional path on team follow-up. is partners RPM progress technology rapid aggressively Our clinical track opportunities pursuing at set with made to to this clinical in developing and building up a fantastic IND out grade team
pediatric with are board, team in XXXX, in a Hagen. have by which X combination received with monotherapy science two Braunstein, and and published we we evaluating been IL-XX enrollment SNO, in at generated combination controlled first additions for recently, year, forged for study encouraging translational has and DIPG trials the we clinical designation FDA data, and Ezickson presented those additions has Doug repopulated medicine. last Track we Phase ASCO, Pagán, in in of Bowden, with Elan study. independence, most Most Dr. Chris our of enrolled Libtayo patient completed in form Next, both Heidi our Furthermore, and The Fast rGBM. Scott followed three as
named Chairman key we players Carl of this mentioned Dr. adding Huang other group. recently the to our James added SAB, are As June to Also, join earlier, and we as board.
additional strong New in data sell pandemic is ZIOPHARM, of our financial accomplishment. weather R&D look a forward coverage the into ongoing in providing output on This COVID-XX lastly, quite key side with we of ensure initiated position visibility have We and during fall. the and analysts in each our list to have clinical presentations programs. a worked to ZIOPHARM details
Our on anticipated milestones remainder had for the six. Slide XXXX detailed of number
for now turn So, our over let review financials. of call to me the Sath a
